XML 58 R44.htm IDEA: XBRL DOCUMENT v3.19.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue recognition (effective January 1, 2018) thru Income Taxes (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Revenue                      
Revenue $ 1,360,628 $ 1,373,334 $ 1,416,078 $ 1,342,484 $ 1,155,069 $ 1,124,957 $ 1,126,464 $ 1,078,740 $ 5,492,524 $ 4,485,230 $ 4,410,388
Manufacturer's rebates earned on total gross profit (in percent)                 17.90% 17.90%  
Manufacturer's rebates incurred on total gross profit (in percent)                 0.40% 0.40%  
Advertising and Marketing Costs                      
Advertising and marketing costs                 $ 3,075 $ 2,251 3,868
Defined Contribution Savings Plans                      
Expenses for defined contribution savings plans                 $ 4,056 $ 2,908 $ 2,665
Share-Based Compensation                      
Expected dividend yield (as a percent)                 0.00% 0.00% 0.00%
Stock Options | Key employees                      
Share-Based Compensation                      
Maximum term of stock options                 10 years    
Expected dividend yield (as a percent)                 0.00%    
Stock Options | Key employees | Tranche One                      
Share-Based Compensation                      
Vesting percentage                 25.00%    
Number of anniversaries dates upon which stock options become exercisable                 3 years    
Stock Options | Key employees | Tranche Two                      
Share-Based Compensation                      
Vesting percentage                 33.00%    
Number of anniversaries dates upon which stock options become exercisable                 2 years    
Restricted Stock Units                      
Share-Based Compensation                      
Vesting period (in years)                 3 years    
Restricted Stock Units | Key employees                      
Share-Based Compensation                      
Vesting period (in years)                 3 years    
Inter-segment eliminations                      
Revenue                      
Revenue                 $ (27,768)    
Specialty                      
Revenue                      
Revenue                 4,790,837 $ 4,472,857 $ 4,410,388
PBM                      
Revenue                      
Revenue                 729,455 12,373  
Oncology | Specialty                      
Revenue                      
Revenue                 2,788,154 2,545,708 2,102,130
Specialty infusion | Specialty                      
Revenue                      
Revenue                 704,872 617,904 505,240
Immunology | Specialty                      
Revenue                      
Revenue                 $ 555,115 $ 561,730 644,173
Hepatitis | Specialty                      
Revenue                      
Revenue                     583,751
Percentage of minimum Revenue                 1,484.70 2,810.63  
Other | Specialty                      
Revenue                      
Revenue                 $ 594,226 $ 466,452 $ 575,094
Other | PBM                      
Revenue                      
Revenue                 23,080 2,032  
Retail networks | PBM                      
Revenue                      
Revenue                 549,760 5,166  
Specialty pharmacy | PBM                      
Revenue                      
Revenue                 88,457 2,914  
Mail order | PBM                      
Revenue                      
Revenue                 $ 68,158 $ 2,261